Acasti Pharma (Acasti Pharma) YoY EBITDA Growth : 28.42% (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Acasti Pharma YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Acasti Pharma's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 28.42%.

Acasti Pharma's EBITDA per Share for the three months ended in Dec. 2023 was $-0.07.

Acasti Pharma YoY EBITDA Growth Historical Data

The historical data trend for Acasti Pharma's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acasti Pharma YoY EBITDA Growth Chart

Acasti Pharma Annual Data

Trend

Feb13

Feb14

Feb15

Feb16

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

YoY EBITDA Growth

Get a 7-Day Free Trial

17.27

59.93

69.57

36.97

2.40

Acasti Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
YoY EBITDA Growth	Get a 7-Day Free Trial															83.39	6.37	35.60	60.00	28.42

Acasti Pharma YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Acasti Pharma's YoY EBITDA Growth for the fiscal year that ended in Mar. 2023 is calculated as:

	YoY EBITDA Growth (A: Mar. 2023 )
=	(EBITDA per Share (A: Mar. 2023 )	-	EBITDA per Share (A: Mar. 2022 ))	/	\| EBITDA per Share (A: Mar. 2022 ) \|
=	(-2.438	-	-2.498)	/	\| -2.498 \|
=	2.40 %

Acasti Pharma's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2023 )
=	(EBITDA per Share (Q: Dec. 2023 )	-	EBITDA per Share (Q: Dec. 2022 ))	/	\| EBITDA per Share (Q: Dec. 2022 )) \|
=	(-0.068	-	-0.095)	/	\| -0.095 \|
=	28.42 %

Acasti Pharma YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Acasti Pharma's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Acasti Pharma (Acasti Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acasti Pharma Inc (NAS:ACST) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

A1P0:Germany

Address

3009 Boulevard de la Concorde East, Suite 102, Laval, QC, CAN, H7E 2B5

Website

https://www.acastipharma.com

Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.

Executives

George Kottayil	director	49 OLD BEAR BROOK ROAD, PRINCETON NJ 08540
A Brian Davis	director	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Edward Neugeboren	director	282 NEW NORWALK ROAD, NEW CANAAN CT 06840
Vimal Kavuru	director	11 MAACKA DRIVE, HOLMDEL NJ 07733
Donald Olds	director	545 PROMENADE DU CENTROPOLIS, SUITE 100, LAVAL A8 H7T 0A3
Amresh Kumar	officer: VP Program Management	3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Carrie D'andrea	officer: VP Clinical Operations	3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Prashant Kohli	officer: Chief Executive Officer	206 CAMBRIDGE LANE, NEWTOWN PA 13940
R. Loch Macdonald	officer: Chief Medical Officer	200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Michael Derby	director	303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
William A Haseltine	director
Rajitha Grace 2018 Irrevocable Trust	10 percent owner	40 BEY LEA ROAD, SUITE C 202, TOMS RIVER NJ 08753
Swami Sambamurty Iyer	10 percent owner	20 TULSA COURT, MONMOUTH JUNCTION NJ 08852
Brian D. Ford	officer: CHIEF FINANCIAL OFFICER	3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
John Canan	director	C/O REV GROUP, INC., 111 EAST KILBOURN AVENUE, SUITE 2600, MILWAUKEE WI 53202